Short Interest in Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Declines By 35.2%

Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totalling 23,700 shares, a decrease of 35.2% from the December 15th total of 36,600 shares. Currently, 0.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 43,400 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Trading of Lakeshore Biopharma

A number of large investors have recently made changes to their positions in the stock. Barclays PLC purchased a new position in shares of Lakeshore Biopharma during the 3rd quarter worth $169,000. FMR LLC acquired a new position in Lakeshore Biopharma in the third quarter valued at $803,000. Finally, Hhlr Advisors LTD. acquired a new position in Lakeshore Biopharma in the third quarter valued at $513,000. Institutional investors and hedge funds own 52.64% of the company’s stock.

Lakeshore Biopharma Trading Down 7.1 %

Shares of NASDAQ:LSB opened at $2.86 on Tuesday. Lakeshore Biopharma has a one year low of $1.88 and a one year high of $11.20. The company’s fifty day moving average is $2.85. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.87 and a current ratio of 1.13.

Lakeshore Biopharma Company Profile

LakeShore Biopharma Co, Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions.